000281825 001__ 281825
000281825 005__ 20251113141926.0
000281825 0247_ $$2doi$$a10.3389/fimmu.2025.1674907
000281825 0247_ $$2pmid$$apmid:41142797
000281825 0247_ $$2pmc$$apmc:PMC12549672
000281825 037__ $$aDZNE-2025-01206
000281825 041__ $$aEnglish
000281825 082__ $$a610
000281825 1001_ $$0P:(DE-2719)9003261$$aLi, Lucie Y$$b0$$eFirst author$$udzne
000281825 245__ $$aBinding of established antinuclear antibodies to neurons depends on tissue fixation and underlying autoantigens.
000281825 260__ $$aLausanne$$bFrontiers Media$$c2025
000281825 3367_ $$2DRIVER$$aarticle
000281825 3367_ $$2DataCite$$aOutput Types/Journal article
000281825 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763039872_32672
000281825 3367_ $$2BibTeX$$aARTICLE
000281825 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281825 3367_ $$00$$2EndNote$$aJournal Article
000281825 520__ $$aAntinuclear antibodies (ANAs) are central biomarkers in rheumatological conditions and can drive disease pathology. Much less is known about the role of ANAs in neurological symptoms, although a number of experimental studies have demonstrated direct effects on neuronal function, for example in neuropsychiatric lupus erythematosus. Moreover, it is unclear whether the ANAs detected in HEp-2 cell-based assays, the gold standard for ANA diagnostics, can also be recognized in modern screening assays for anti-neuronal autoimmunity, such as staining on rodent brain sections or neuronal cultures. In this study, we therefore conducted a comparative mapping of ANA-positive sera with well-characterized HEp-2 patterns to central nervous system (CNS) tissue, utilizing fixed and unfixed murine brain sections and primary murine neurons. We screened 74 ANA-positive sera classified into 14 individual patterns and combinations thereof. Majority of the samples reacted with fixed primary neurons (99%, 73/74 sera), followed by fixed brain sections (93%, 69/74), but much less to unfixed mouse brain (54%, 40/74). While the PM/SCL- and RPOI-positive sera showed no binding to unfixed brain sections, the U1RNP (U1 nuclear ribonucleoprotein particle) and FBLN (fibrillarin) ANAs reacted strongly across all assays, indicating differences in antigen accessibility. These findings suggest that the majority of ANAs can interact with neural components, which may obscure the detection of other anti-neuronal autoantibodies. The foundational mapping of ANA binding in CNS tissue provided here can also facilitate recognition of 'CNS-specific ANAs,' which bind to neuronal autoantigens but not to HEp-2 cells. Future studies should explore the association with certain neurological manifestations and the role of ANAs in neuronal pathology.
000281825 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281825 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281825 650_7 $$2Other$$aANA
000281825 650_7 $$2Other$$aHEp-2
000281825 650_7 $$2Other$$aanti-neuronal antibodies
000281825 650_7 $$2Other$$aautoimmunity
000281825 650_7 $$2Other$$aimmunofluorescence
000281825 650_7 $$2NLM Chemicals$$aAntibodies, Antinuclear
000281825 650_7 $$2NLM Chemicals$$aAutoantigens
000281825 650_2 $$2MeSH$$aAnimals
000281825 650_2 $$2MeSH$$aNeurons: immunology
000281825 650_2 $$2MeSH$$aNeurons: metabolism
000281825 650_2 $$2MeSH$$aAntibodies, Antinuclear: immunology
000281825 650_2 $$2MeSH$$aAntibodies, Antinuclear: metabolism
000281825 650_2 $$2MeSH$$aMice
000281825 650_2 $$2MeSH$$aAutoantigens: immunology
000281825 650_2 $$2MeSH$$aHumans
000281825 650_2 $$2MeSH$$aTissue Fixation
000281825 650_2 $$2MeSH$$aBrain: immunology
000281825 650_2 $$2MeSH$$aBrain: metabolism
000281825 650_2 $$2MeSH$$aFemale
000281825 650_2 $$2MeSH$$aMale
000281825 7001_ $$aHöltje, Markus$$b1
000281825 7001_ $$0P:(DE-2719)2814341$$aRasmussen, Helle Foverskov$$b2$$udzne
000281825 7001_ $$aHalle, Lennard$$b3
000281825 7001_ $$aMayrhofer, Marie$$b4
000281825 7001_ $$aBlüthner, Martin$$b5
000281825 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b6$$eLast author$$udzne
000281825 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2025.1674907$$gVol. 16, p. 1674907$$p1674907$$tFrontiers in immunology$$v16$$x1664-3224$$y2025
000281825 8564_ $$uhttps://pub.dzne.de/record/281825/files/DZNE-2025-01206.pdf$$yOpenAccess
000281825 8564_ $$uhttps://pub.dzne.de/record/281825/files/DZNE-2025-01206.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003261$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000281825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814341$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000281825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000281825 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281825 9141_ $$y2025
000281825 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000281825 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281825 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-29T15:23:07Z
000281825 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-29T15:23:07Z
000281825 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281825 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-29T15:23:07Z
000281825 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000281825 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000281825 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000281825 980__ $$ajournal
000281825 980__ $$aVDB
000281825 980__ $$aUNRESTRICTED
000281825 980__ $$aI:(DE-2719)1810003
000281825 9801_ $$aFullTexts